Siegfried opens drug substances R&D centre
Submitted by:
Andrew Warmington
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its
Siegfried breaks ground on R&D centre
Submitted by:
Andrew Warmington
Siegfried has broke ground for its new global R&D centre for drug substances at its
Evonik realigns Health Care
Submitted by:
Andrew Warmington
In order to “maximise customer centricity and market focus” and continue an ongoing transition into
Quotient integrates drug substance into platform
Submitted by:
Andrew Warmington
Quotient Sciences, a UK-based firm that describes itself as a “drug development and manufacturing accelerator”
Quotient to expand Alnwick
Submitted by:
Andrew Warmington
Quotient Sciences is to invest £6.3 million to expand drug substance manufacturing at the site
Cambrex invests in Sweden
Submitted by:
Andrew Warmington
Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing